Saxagliptin & Heart Failure

Type 2 Diabetes Drug Linked to Increased Risk of Heart Failure

The U.S. Food and Drug Administration (FDA) announced in 2014 that it would be investigating the heart failure risk of saxagliptin, a drug prescribed to treat type 2 diabetes. A recent safety update from the FDA states that their safety review “found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. As a result, we are adding new warnings to the drug labels about this safety issue.”

If you or a loved one was prescribed a type 2 diabetes drug containing saxagliptin and suffered a serious adverse side effect, please contact the attorneys at Spangenberg Shibley & Liber today. You may be entitled to compensation, so contact us to learn your legal rights and options!

Recommended Reading

Saxagliptin and Alogliptin-Containing Medicines

With the release of their new warning labels, the FDA listed the brand names of drugs containing saxagliptin and alogliptin:

  • Onglyza
  • Kombiglyze XR
  • Nesina
  • Kazano
  • Oseni

Patients Who Received Saxagliptin More Likely to Be Hospitalized for Heart Failure

The FDA evaluated two large clinical trials, and found that in the saxagliptin trial, 3.5% of patients who took this drug were hospitalized for heart failure, compared to 2.8% of patients who took the placebo. Patients who take saxagliptin-containing drugs to treat type 2 diabetes are at an increased risk of heart failure, according to the study.

Learn your legal rights and options!

Contact the experienced attorneys at Spangenberg Shibley & Liber if you or a loved one suffered harm as a result of taking saxagliptin. Our firm is experienced in representing those who have been harmed by dangerous and defective prescription drugs, so we encourage you to get in touch with us today for a free review of your case.

Call (216) 600-0114 or fill out our free online form to get started.